24 April 2024 - Conditional marketing authorisation is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT study.

Travere Therapeutics and CSL Vifor today announced that the European Commission has granted conditional marketing authorisation for Filspari (sparsentan) for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

Read Travere Therapeutics press release